Stockscreener 앱 받기
21.40
3.34%
-0.74
시간 외 거래:
21.50
0.10
+0.47%
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Is Syndax Pharmaceuticals (SNDX) Pricing Reflect Pipeline Progress Or Stretching Recent Share Gains - simplywall.st
SNDX Receives Buy Rating as Citigroup Raises Price Target to $57 - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $57.00 Price Target at Citigroup - MarketBeat
Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs - Bitget
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2025 Earnings Call Transcript - Insider Monkey
Barclays Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX) - The Globe and Mail
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Syndax Pharmaceuticals (NASDAQ:SNDX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story? - Yahoo Finance
Syndax (SNDX) Q4 2025 Earnings Call Transcript - Intellectia AI
SNDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Syndax Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
Discipline and Rules-Based Execution in SNDX Response - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Syndax Pharmaceuticals (SNDX) - The Globe and Mail
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus
Syndax Pharmaceuticals (SNDX) Reports Strong 2025 Earnings and Growth Prospects - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Announces Quarterly Earnings Results, Misses Expectations By $0.12 EPS - MarketBeat
Syndax Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Syndax (SNDX) Projects Stable Operating Expenses and Path to Pro - GuruFocus
Syndax (SNDX) Exceeds Revenue Expectations, Anticipates Continued Growth - GuruFocus
Syndax Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Q4 2025 Syndax Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Earnings Flash (SNDX) Syndax Pharmaceuticals, Inc. Reports Q4 Revenue $68.7M, vs. FactSet Est of $64.3M - marketscreener.com
BRIEF-Syndax Pharmaceuticals Q4 Operating Expenses USD 131.276 Million - TradingView
Cancer drug maker Syndax posts $172M sales, eyes profitability - Stock Titan
Syndax faces earnings test as cancer drug launches accelerate By Investing.com - Investing.com UK
Syndax faces earnings test as cancer drug launches accelerate - Investing.com India
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Syndax Pharmaceuticals, Inc. announces that patient enrollment has been completed for its Phase II clinical trial of Axatilimab for idiopathic pulmonary fibrosis (IPF). - Bitget
VIX Spike: Is Syndax Pharmaceuticals Inc stock showing strong momentumBull Run & High Yield Equity Trading Tips - baoquankhu1.vn
Biotech CEO plans three March investor Q&As in Boston and Miami - Stock Titan
Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Monday - Defense World
Aberdeen Group plc Grows Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Is Syndax Pharmaceuticals Inc. a speculative investment2025 Price Momentum & Accurate Trade Setup Notifications - mfd.ru
Earnings Miss: Does Syndax Pharmaceuticals Inc. have strong fundamentalsQuarterly Investment Review & Safe Capital Investment Plans - mfd.ru
Can Syndax Pharmaceuticals Inc. stock double in the next yearInsider Selling & Precise Trade Entry Recommendations - mfd.ru
Syndax Pharmaceuticals (SNDX) Stock Analysis: An 88% Potential Upside Ignites Investor Interest - DirectorsTalk Interviews
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call ... - Bluefield Daily Telegraph
Syndax to Announce Fourth Quarter and Full Year 2025 - GlobeNewswire
Cancer drug maker Syndax to review 2025 results in Feb. 26 earnings call - Stock Titan
Syndax Pharmaceuticals Highlights Revuforj, Niktimvo Sales Surge and 2026 Milestones at Guggenheim Conf - Defense World
Why Analysts See Syndax Pharmaceuticals (SNDX) Story Evolving With New Deals And Refined Valuation - Yahoo Finance
Behavioral Patterns of SNDX and Institutional Flows - Stock Traders Daily
How Revuforj’s Global Access Push At Syndax Pharmaceuticals (SNDX) Has Changed Its Investment Story - Sahm
Is Syndax Pharmaceuticals (SNDX) Pricing Reflecting Recent Biotech Reassessment Or Long Term Potential - Yahoo Finance
Does Syndax Pharmaceuticals Inc. meet Warren Buffett’s criteriaShare Buyback & Consistent Profit Alerts - mfd.ru
BofA Raised Syndax (SNDX) PT to $28, Cites Heavy Pre-Announcements Lowering Earnings Impact - Bitget
A Look At Syndax Pharmaceuticals (SNDX) Valuation After Revuforj Data And New Managed Access Program - Sahm
11 Most Promising Low-Cost Stocks to Buy Now - Insider Monkey
Have Insiders Sold Syndax Pharmaceuticals Shares Recently? - simplywall.st
Is Syndax Pharmaceuticals Inc. still a buy after recent gainsJuly 2025 Sentiment & Fast Entry High Yield Stock Tips - mfd.ru
SNDX: Robust product growth, expanding indications, and disciplined spending set up a path to profitability - TradingView
Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 (NASDAQ:SNDX) - Seeking Alpha
Insider Selling: Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 17,159 Shares of Stock - MarketBeat
Keith Goldan Sells 3,410 Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - MarketBeat
Syndax Pharmaceuticals CEO Metzger sells $360k in stock By Investing.com - Investing.com Canada
Candriam S.C.A. Raises Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Is Syndax Pharmaceuticals Inc. stock attractive for income investorsQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - mfd.ru
Setup Watch: Will Syndax Pharmaceuticals Inc benefit from green energy policiesMarket Trend Report & High Accuracy Trade Alerts - baoquankhu1.vn
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Michael Metzger Sells 7,412 Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - MarketBeat
Insider Selling: Syndax Pharmaceuticals (NASDAQ:SNDX) CFO Sells 2,082 Shares of Stock - MarketBeat
Syndax Pharmaceuticals CEO sells $152,835 in SNDX stock By Investing.com - Investing.com Canada
5.71%
0.02%
자본화:
|
볼륨(24시간):